Reasons to pause

A prescription is treated as optional

The federal rule recorded in September 2026 made dispensing a prescription medicine without a valid prescription unlawful. FDA also identified the absence of a prescription requirement as an online-pharmacy warning sign. The federal agency that reviews drugs uses the abbreviation FDA for Food and Drug Administration. Ask what assessment comes before the prescribing decision and who makes it.

Do not confuse a short intake form with a settled care plan. Ask who reviews it, how more questions are asked, and how you can ask yours. If the service cannot describe that exchange, the process question remains open regardless of how easy the payment page is to use.

The proposal is a menu choice

The medical-board federation's May 2026 guidance said a patient's menu selection alone did not meet the standard for prescribing. Its recorded policy also rejected static questionnaires that could not gather what proper assessment required. Static means the questions and answer choices stay fixed, with no back-and-forth to ask more about what you wrote. These are professional policies; state rules govern the binding requirements.

Ask how the professional reaches a decision beyond the selection made on a page. Can they propose another assessment or decline the medicine? Can you discuss a concern that the form did not ask about? Look for an explanation of the assessment rather than a promise that it will end in a prescription.

Compare the claims with the record

In the September 2026 record, calling a compounded preparation FDA-approved was a false claim. FDA registration and drug listing also did not mean approval or permission to market a product. Ask which specific record a service is relying on and what it actually confirms.

An NDC, or National Drug Code, was not evidence of FDA approval as of September 2026. A directory entry can look official while answering a different question. Bring the claim and the proposed medicine name together, then ask the professional to explain the difference.

A research label stands in for care

FDA's 2026 letters alleged that certain research-labeled products were unapproved human drugs based on how the websites promoted them. Those letters were enforcement allegations about named firms rather than court findings. A research label does not provide the assessment and continuing conversation that the search for a prescriber calls for.

Return to the exact medicine name, its status, and the person taking responsibility for the assessment. You can leave a page without resolving its claims. There is no need to resolve that classification from a sales explanation.

The pharmacy or the later conversation disappears

Among FDA’s telehealth warning signs is receiving medicine without a licensed doctor available to discuss questions afterward. By September 2026, FDA had described fraudulent compounding labels bearing either invented pharmacy names or the names of pharmacies that had not produced the drugs. Obtain the complete pharmacy name, then match it with the state board’s record.

Official-looking seals and guarantees are things scammers can imitate, the Federal Trade Commission cautions. Keep the check grounded in a public record and a clear answer from the service. If you already have a medicine-related concern, move to problems that need a response; do not wait to finish comparing websites before seeking appropriate help.